The emerging role of immunotherapy in cholangiocarcinoma
Ghassan Abou-Alfa, MD, MBA, Memorial Sloan Kettering Cancer Center, New York, NY, discusses developments in treating cholangiocarcinoma with immunotherapy. Findings from the Phase III TOPAZ-1 trial (NCT03875235) of durvalumab in combination with gemcitabine plus cisplatin have demonstrated enhanced survival rates in patients with advanced biliary tract cancer. Consequently, existing targeted therapies such as pemigatinib and ivosidenib have moved to the second line setting and infigratinib has been discontinued as a therapy. This interview took place virtually at the 2022 Great Debates & Updates in Gastrointestinal Malignancies Congress.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
No comments found